Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An oncolytic virus that kills cancer cells and triggers immune responses against tumors shows promise for children with brain cancer.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Tumor-infiltrating lymphocytes are T cells that know how to recognize and fight cancer.
Study finds 4% of patients with metastatic renal cell carcinoma developed asymptomatic brain metastases, correlating to poorer outcomes.
The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.
Studies have shown an alarming drop in screenings—and more advanced cancer—during the COVID-19 pandemic.
Weight-loss surgery especially reduced obesity-related cancers in people with liver cirrhosis.
Screening and education provided in the NCI Familial Melanoma Study could lead to earlier detection of melanoma in melanoma-prone families.
The response rate was nearly 50% for people with breast, colon, pancreatic and other cancers.
Mixed-size DNA fragments in a blood sample may predict residual cancer as well as MRI scans.
After a median follow-up of 13 months, four of the five patients had ongoing complete remission.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
Men with a high genetic risk of prostate cancer can reduce their risk of developing a lethal form of the disease by healthy living.
Colorectal cancer in people under 50 has risen dramatically in recent decades.
IUDs were even more effective at preventing endometrial cancer in women with a precancerous condition.
CU Cancer Center’s Joaquin Espinosa, PhD, and his team investigated hypoxia-inducible factors in tumor growth and suppression.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.